Appointment of Dr. Kalpesh Barot, MD Completes Phase One of ADIA Nutrition’s Medical Division
ADIA Nutrition (OTC Pink: ADIA) has announced the completion of its Board of Medical Directors with the appointment of Dr. Kalpesh Barot, MD, an oncologist from the Southwest Cancer Center. This unanimous decision by the Board, led by Dr. Monica Sher, MD, and Dr. Richard Edwards, DO, marks a significant milestone for the company. Dr. Barot will focus on overseeing ADIA's aHSCT (autologous hematopoietic stem cell transplantation) treatments for Multiple Sclerosis (MS) patients.
The appointment strengthens ADIA Nutrition's medical leadership and expertise in advancing healthcare solutions. Dr. Barot's extensive background in oncology is expected to be instrumental in refining aHSCT protocols and expanding treatment options for MS patients. With the medical board now complete, ADIA Nutrition is prepared to establish and refine all protocols and procedures for their aHSCT treatment for MS, aiming to make it a more accessible and effective option.
ADIA Nutrition (OTC Pink: ADIA) ha annunciato il completamento del suo Consiglio dei Direttori Medici con la nomina del Dr. Kalpesh Barot, MD, oncologo del Southwest Cancer Center. Questa decisione unanime del Consiglio, guidato dal Dr. Monica Sher, MD, e dal Dr. Richard Edwards, DO, rappresenta un traguardo significativo per l'azienda. Il Dr. Barot si concentrerà sulla supervisione dei trattamenti aHSCT (trapianto autologo di cellule staminali ematopoietiche) per i pazienti affetti da Sclerosi Multipla (SM).
La nomina rafforza la leadership e l'expertise medica di ADIA Nutrition nel promuovere soluzioni sanitarie. Il vasto background del Dr. Barot in oncologia è previsto per essere strumentale nel perfezionare i protocolli aHSCT e nell'espandere le opzioni di trattamento per i pazienti con SM. Con il consiglio medico ora completo, ADIA Nutrition è pronta per stabilire e perfezionare tutti i protocolli e le procedure per il loro trattamento aHSCT per la SM, portando a renderlo un'opzione più accessibile ed efficace.
ADIA Nutrition (OTC Pink: ADIA) ha anunciado la finalización de su Consejo de Directores Médicos con la designación del Dr. Kalpesh Barot, MD, un oncólogo del Southwest Cancer Center. Esta decisión unánime del Consejo, liderado por la Dra. Monica Sher, MD, y el Dr. Richard Edwards, DO, marca un hito significativo para la empresa. El Dr. Barot se enfocará en supervisar los tratamientos aHSCT (trasplante autólogo de células madre hematopoyéticas) para pacientes con Esclerosis Múltiple (EM).
La designación refuerza el liderazgo y la experiencia médica de ADIA Nutrition en la promoción de soluciones de atención médica. Se espera que la amplia experiencia del Dr. Barot en oncología sea fundamental para perfeccionar los protocolos aHSCT y ampliar las opciones de tratamiento para los pacientes con EM. Con el consejo médico ahora completo, ADIA Nutrition está preparada para establecer y refinar todos los protocolos y procedimientos para su tratamiento aHSCT para EM, con el objetivo de hacerlo una opción más accesible y efectiva.
ADIA Nutrition (OTC Pink: ADIA)는 의료 이사회의 완성을 발표하며 Dr. Kalpesh Barot, MD, Southwest Cancer Center의 종양학자를 임명했습니다. 이사회가 Dr. Monica Sher, MD, 및 Dr. Richard Edwards, DO에 의해 이끌어진 이 만장일치 결정은 회사에 중요한 이정표를 의미합니다. Barot 박사는 다발성 경화증 (MS) 환자들을 위한 aHSCT (자가 조혈 줄기세포 이식) 치료 감독에 집중할 것입니다.
이번 임명은 ADIA Nutrition의 의료 리더십과 의료 솔루션을 발전시키는 전문성을 강화합니다. Barot 박사의 방대한 종양학 배경은 aHSCT 프로토콜을 개선하고 MS 환자들을 위한 치료 옵션을 확장하는 데 중요한 역할을 할 것으로 기대됩니다. 의료 이사회가 이제 완성됨에 따라, ADIA Nutrition은 MS를 위한 aHSCT 치료의 모든 프로토콜과 절차를 수립하고 개선할 준비가 되어 있으며, 이를 보다 접근 가능하고 효과적인 옵션으로 만들기 위해 노력하고 있습니다.
ADIA Nutrition (OTC Pink : ADIA) a annoncé l'achèvement de son Conseil des Directeurs Médicaux avec la nomination du Dr. Kalpesh Barot, MD, oncologue du Southwest Cancer Center. Cette décision unanime du Conseil, dirigé par le Dr Monica Sher, MD, et le Dr Richard Edwards, DO, représente une étape importante pour l'entreprise. Le Dr Barot se concentrera sur la supervision des traitements aHSCT (transplantation autologue de cellules souches hématopoïétiques) pour les patients atteints de Sclérose en Plaques (SEP).
La nomination renforce le leadership médical d'ADIA Nutrition et son expertise dans le développement de solutions de santé. L'expérience approfondie du Dr Barot en oncologie devrait être déterminante pour affiner les protocoles aHSCT et élargir les options de traitement pour les patients atteints de SEP. Avec le conseil médical désormais complet, ADIA Nutrition est prête à établir et à affiner tous les protocoles et procédures pour son traitement aHSCT pour la SEP, visant à le rendre plus accessible et efficace.
ADIA Nutrition (OTC Pink: ADIA) hat den Abschluss seines Medizinischen Direktorats bekannt gegeben, indem Dr. Kalpesh Barot, MD, ein Onkologe vom Southwest Cancer Center, ernannt wurde. Diese einstimmige Entscheidung des Direktorats, geleitet von Dr. Monica Sher, MD, und Dr. Richard Edwards, DO, stellt einen bedeutenden Meilenstein für das Unternehmen dar. Dr. Barot wird sich darauf konzentrieren, die aHSCT (autologe hämatopoetische Stammzelltransplantation) Behandlungen für Patienten mit Multipler Sklerose (MS) zu überwachen.
Die Ernennung stärkt die medizinische Führung und Expertise von ADIA Nutrition in der Weiterentwicklung von Gesundheitslösungen. Der umfangreiche Hintergrund von Dr. Barot in der Onkologie wird als entscheidend angesehen, um die aHSCT-Protokolle zu verfeinern und die Behandlungsoptionen für MS-Patienten zu erweitern. Mit dem nun vollständigen medizinischen Vorstand ist ADIA Nutrition bereit, alle Protokolle und Verfahren für ihre aHSCT-Behandlung für MS zu etablieren und zu verfeinern, um sie zugänglicher und effektiver zu machen.
- Appointment of Dr. Kalpesh Barot strengthens ADIA Nutrition's medical expertise
- Completion of Board of Medical Directors enhances company's capabilities in MS treatment
- Dr. Barot's oncology background expected to improve aHSCT protocols for MS patients
- Company now prepared to establish and refine aHSCT treatment procedures
- None.
WINTER PARK, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- ADIA Nutrition (OTC Pink: ADIA) is excited to announce the completion of its Board of Medical Directors with the appointment of Dr. Kalpesh Barot, MD, a distinguished oncologist from the Southwest Cancer Center. This decision comes unanimously from the Board, led by Dr. Monica Sher, MD, and Dr. Richard Edwards, DO, in recognition of Dr. Barot’s exceptional qualifications and experience.
Dr. Barot’s impressive resume and extensive expertise in oncology will bring invaluable insight to ADIA Nutrition’s mission to advance healthcare solutions. His focus will be on overseeing ADIA’s aHSCT (autologous hematopoietic stem cell transplantation) treatments, a cutting-edge therapy designed to offer new hope for patients suffering from Multiple Sclerosis (MS).
"Dr. Barot’s appointment to our Board marks a significant milestone for ADIA Nutrition,” said Dr. Monica Sher, MD, Chair of the Board. “His extensive background in oncology and commitment to patient care align perfectly with our vision to provide innovative and effective treatments for MS patients. We are confident that his contributions will further our mission to revolutionize patient outcomes through advanced therapeutic solutions.”
Dr. Barot joins an already accomplished team of medical experts at ADIA Nutrition, bringing with him a wealth of knowledge gained through his tenure at the Southwest Cancer Center. His role will be pivotal in enhancing the aHSCT protocols and ensuring the highest standards of care for patients undergoing this transformative treatment.
Board member and CEO Larry Powalisz, added, “Adding Dr. Barot to our Board represents our dedication to continually elevating the quality and scope of our medical leadership. His background in oncology will be instrumental in refining our aHSCT programs and expanding the horizons of treatment for MS patients.”
With the completion of their medical board, ADIA Nutrition is now fully prepared to establish and refine all the protocols and procedures for their aHSCT treatment for MS. The board's expertise, now fully assembled, will guide the development of these protocols, aiming to make aHSCT a more accessible and effective treatment option for MS.
For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adia-med.com
Website: www.biolete.com
Website: www.cementfactory.com
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dc6cbab5-fd39-4c6f-8c66-c4ba3f581d12
FAQ
Who is Dr. Kalpesh Barot and what is his role at ADIA Nutrition (ADIA)?
What is the significance of Dr. Barot's appointment for ADIA Nutrition (ADIA)?
How will Dr. Barot's appointment impact ADIA Nutrition's (ADIA) MS treatment development?
What is ADIA Nutrition's (ADIA) next step following the completion of its Medical Board?
